Quality Control Inspector 1

FDA flags quality system lapses at Medline facility over device risks. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. The U.S. Food and Drug Administration has issued a warning letter to Medline Inc. (NASDAQ:MDLN), following an inspection that identified significant quality system violations tied to its cardiovascular device kits, raising concerns about patient safety and regulatory compliance. FDA flags manufacturing and quality system failures. The inspection, conducted between December 1 and December 12, 2025, at Medline's New York facility, found that the company's angiographic control syringes and related components failed to meet current good manufacturing practice standards. The FDA determined the devices were "adulterated" under federal law due to deficiencies in manufacturing controls, quality systems, and compliance with established regulations. CAPA process breakdown raises safety concerns. The letter dated March 25 highlighted Medline's failure to properly implement corrective and preventive action (CAPA) procedures. Despite 221 complaints and 177 medical device reports tied to syringe disconnections, the company's corrective actions - such as scrapping inventory and increasing cleaning frequency - were deemed insufficient relative to the risk. The FDA noted inconsistencies in Medline's risk assessments, particularly where internal analyses flagged severe risks like air embolism, while the company classified the overall risk as low. Complaint trends also remained above established thresholds even after corrective actions were introduced, yet the company did not escalate or reopen investigations as required. Device recall and ongoing investigations. Medline acknowledged the shortcomings, closed the initial CAPA, and initiated new investigations alongside a product removal plan. The company submitted a formal report to the FDA in March 2026 outlining the removal of affected devices. However, regulators flagged gaps in the scope and timeline of these actions, including unclear investigation deadlines and inconsistencies in manufacturing data tied to complaint rates. Medline contamination risks and cleaning deficiencies. The FDA also cited failures in maintaining cleanroom standards, with visible particulate matter found on manufacturing equipment. More than 100 complaints related to foreign material contamination were recorded over two years. While Medline implemented corrective cleaning measures and updated procedures, the FDA said the company did not adequately assess the impact on products already in the market. Further violations involved inadequate design verification processes. The FDA found insufficient documentation supporting testing decisions for device components, raising questions about whether all affected products met required standards. Regulatory risks and next steps. The FDA warned that failure to address these issues could lead to enforcement actions, including fines or product seizures. Medline has been directed to submit a detailed remediation plan within 15 business days and align all corrective actions with updated Quality Management System Regulation requirements that took effect in February 2026. In February, Medline identified electrical safety risks with its Medline Basic Homecare Beds that may lead to fire. MDLN Price Action: Medline shares were up 2.93% at $45.64 at the time of publication on Thursday, according to Benzinga Pro data. Everyone Bought NVIDIA. The Smart Money Is Now Buying What NVIDIA Needs to Run. The chip trade is crowded. Valuations are stretched. The investors who made money on Phase 1 of AI are already repositioning into the one thing every data center depends on: uninterrupted power. Natural gas and nuclear are the only sources that can deliver it at scale - and one small company just landed a deal to power multiple new hyperscale data centers. Posted In:

Medline hit with FDA warning letter over angiographic syringe manufacturing failures. An FDA inspection of Medline's facilities in December 2025 found that the company fell short of certain good manufacturing practice requirements. The US Food and Drug Administration (FDA) has issued a warning to Medline over deficiencies relating to the company's angiographic syringe manufacturing protocols. The warning letter was only just made publicly available and is dated 25 March. Penned by Barbara Marsden, director of the Office of Regulatory Programs and Office of Product Evaluation and Quality at the FDA's Center for Devices and Radiological Health (CDRH), the document communicates findings from a facility inspection to Medline CEO Jim Boyle. Following an inspection of the company's New York manufacturing facility in December 2025, the letter said that the FDA's inspecting agent determined that Medline's NAMIC-branded angiographic control syringes were "adulterated". This means that good manufacturing practice requirements were not adhered to. The New York facility produces both the syringes and associated kits used to inject radiographic contrast media into patients' blood vessels for several heart procedures. Violations identified by the FDA following the inspection included failures by Medline to "establish and maintain" procedures for implementing corrective and preventive action around complaints received about the NAMIC syringes. Medline initiated corrective procedures, attributing syringe connection issues to excess silicone. The FDA noted that Medline's declaration of a low risk to health was inconsistent given the potential for air embolisms. A syringe air embolism occurs when air bubbles enter a vessel, potentially blocking blood flow. "Your firm's corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the (b)(4) machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 medical device reports (MDRs) for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians," the letter continued. Richard Kalita, senior manager of quality assurance at Medline, responded to the FDA's observations in two letters dated 13 January and 27 February 2026. However, the agency deemed the company's planned response to the observed range of issues as inadequate. "No information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue," Marsden wrote. "Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective," Marsden continued. Other remediation issues identified by the FDA include Medline's "failure to establish and maintain procedures for verifying the device design" and to "establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met". From the date of the letter's issuance, the FDA concluded that Medline has 15 days to respond to the warning letter. It must provide "specific steps" it intends to take to address the noted violations and inadequate responses outlined in Kalita's prior correspondence with the agency, as well as an explanation of how the company plans to prevent the same, or similar, violations from occurring again. The FDA's warning letter represents the first major hurdle Medline will have to navigate since going public. The company went public on the Nasdaq stock exchange on 17 December 2025, raising $6.26bn in an upsized initial public offering (IPO) that valued the company at $46bn, making it the largest healthcare IPO in history. Give your business an edge with our leading industry insights.

Medline hit with FDA Warning over CAPA failures, cleanroom violations, & design testing deficiencies. Medline Industries faces FDA scrutiny for significant quality system violations. Amanda Pedersen, Senior Editor, MD+DI, Informa Markets - Engineering April 9, 2026 At a glance. * FDA warns Medline Industries for CAPA, cleanroom, and design verification violations. * Syringe disconnection risks and contamination issues raise serious concerns. * Regulatory actions loom if corrective measures are delayed. Medline is in hot water with FDA. The agency inspected the company's Glen Falls, NY, facility in December 2025 and found multiple violations, resulting in a seven-page warning letter dated March 25 and posted to the agency's website this week. The Medline facility in question manufactures and assembles medical devices, including cardiovascular procedure kits and Namic angiographic control syringes. A Medline spokesperson told MD+DI the company is "committed to quality, patient safety, and regulatory compliance." "We are aware of the FDA Warning Letter following a recent inspection of our Namic facility," the spokesperson said. "We take these matters seriously, are working directly with the FDA to address the observations and have initiated actions to strengthen our processes where needed." Failure to implement CAPA procedures. According to the warning letter, Medline failed to implement corrective and preventive action (CAPA) procedures. FDA said the company did not take actions commensurate with the risks identified for the Namic angiographic control syringes, despite receiving 221 complaints and filing 177 Medical Device Reports (MDRs) related to disconnections. One MDR involved the injection of air into a patient (a potentially fatal condition), and another involved biohazard exposure of a clinician. FDA noted that Medline's Health Hazard Evaluation underestimated risks, which contradicted the firm's design failure modes and effectiveness analysis (dFMEA). Corrective actions were inadequate, according to FDA, and the issue persisted with high complaint rates post-corrective action. Ineffective CAPA monitoring. According to FDA's warning letter, Medline failed to route CAPAs back to earlier phases or open additional CAPAs when corrective actions were ineffective, as required by the company's internal procedures. Complaint rates exceeded thresholds, but no timely actions were taken, according to the letter. Failure to maintain cleanroom equipment. FDA accused Medline of not following its own cleaning procedures for controlled environments, leading to visible particulate accumulation on equipment in cleanrooms. The warning letter notes that 114 complaints were received regarding foreign matter or hair in products, but no corrective actions were taken to assess the impact on products already in the field. FDA said it found Medline's cleaning schedules and sign-off sheets inadequate, as they failed to include specific instructions for cleaning the tops of manufacturing equipment. Inadequate design verification testing. FDA also noted that Medline's design verification for polycarbonate female luer connectors was insufficient, as testing was performed on only one connector, which did not represent all affected connectors. The connector also was not included in the final version of the Design Change Analysis Form (DCAF), FDA critiqued. Justifications for part selection and testing scope were missing or inadequate, FDA said. Inadequate responses from Medline. FDA acknowledged that Medline submitted responses to the noted violations on January 13, 2026, and February 27, 2026, but the agency deemed them inadequate due to: * Lack of timely and effective corrective actions. * Insufficient assurance that systemic issues would be addressed. * Failure to provide clear timelines and evidence for resolving deficiencies. FDA's expectations and next steps. According to the FDA warning letter, Medline must address all deficiencies comprehensively and provide updates on corrective actions. The company also must ensure compliance with the new Quality Management System Regulation (QMSR), which became effective Feb. 2. And finally, Medline must submit a written response within 15 business days detailing specific steps taken to address the violations, including supporting evidence and timelines. Potential consequences for Medline. Failure to address violations may result in regulatory actions against Medline, FDA noted, including seizure, injunction, or civil penalties; impact on federal contracts and premarket approvals for class III devices; and denial of Certificates to Foreign Governments (CFG). Senior Editor, MD+DI, Informa Markets - Engineering Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006. Amanda Pedersen poses with her Jesse H. Neal Awards plaque after winning the "Best Commentary" category with Pedersen's POV After 18 years of reporting on the medical device and diagnostics industry, Amanda has no fear of speaking truth to power. That's important in an industry in which over half of the top 100 companies report more than $1 billion in revenue. In her weekly Pedersen's POV opinion column, she isn't afraid to shine a light on industry leaders for bad behavior. Her insights spark conversation about what price is too high to pay for corporate success in medtech. Amanda graduated from Northern Illinois University in 2003 with a B.A. in Communication. After a few years reporting for community newspapers, including the Galesburg Register Mail in Galesburg, IL, and the Marietta Daily Journal in Marietta, GA, Amanda spent 10 years covering the medical device industry for Medical Device Daily (now known as BioWorld MedTech). Amanda joined the editorial staff of MD+DI in December 2016.